# A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients

> **NCT03629080** · PHASE2 · COMPLETED · sponsor: **Hookipa Biotech GmbH** · enrollment: 83 (actual)

## Conditions studied

- Cytomegalovirus (CMV) Infection
- Kidney Transplantation

## Interventions

- **BIOLOGICAL:** HB-101 vaccine
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT03629080
- **Lead sponsor:** Hookipa Biotech GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-12
- **Primary completion:** 2022-06-22
- **Final completion:** 2022-06-22
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03629080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03629080, "A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03629080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*